VP / Head of Clinical Development - ONCOLOGY

Your Responsibilities:  GSK Oncology includes clinical development of one or more assets in Immuno-Oncology (IO), Oncology Cell Therapy (OCT), and Cancer Epigenetics (CE). These three Discovery Performance Units (DPUs) focus on developing innovative therapeutics for treating various oncologic and hematologic indications.  In IO, anti-BCMA antibody-drug conjugate has demonstrated unprecedented efficacy ( 60% overall response rate) in refractory/relapsed multiple myeloma. Other IO assets include the first-in-class anti-ICOS agonist antibody, anti-OX-40 agonist antibody, TLR4 agonist, and multiple near clinical stage assets.  In OCT, GSK recently excised the early opt-in option for an investigational NY-ESO-1 TCR-modified T cell therapy from AdaptImmune. This novel cell therapy delivered a 50% ORR in synovial sarcoma, and it being investigated in multiple other solid tumors.  The CE clinical pipeline includes multiple clinical stage assets including BET, LSD1, and PRMT5 inhibitors.  EXPERIENCE / ACCOUNTABILITIES GSK seeks an outstanding oncology physician executive to join the leadership team of Dr. Axel Hoos, Senior VP- Oncology Therapy Area Head.   Accountabilities:   The Head of Clinical Development is the senior clinical development expert of the Oncology Therapeutic Area (TA) with oversight for the development strategies across all programs of the Oncology asset portfolio. The Head of clinical development has direct line function responsibility for all clinical personnel including physicians, clinical scientists in the TA, and Disease Strategy Leads (DSLs) who drive cross-asset strategy. He/she works in a matrix role to support Early Development Teams (EDTs) for preparing programs for entry into clinical development and Medicine Development Teams (MDTs) for driving clinical strategy for late stage assets.  Further, the Head of clinical Development chairs the Protocol Review Forum (PRF) ensuring highest level quality for all TA clinical protocols. He/she is a member of the Portfolio Review Committee (PRC) overseeing asset progression across the portfolio and participates in governance committee reviews for R&D assets. He/she reports tothe TA Head of Oncology. The Head of Clinical Development provides clinical development expertise, strategic leadership, Oncology disease area expertise , and Prescriber Insight for a Therapeutic Area Unit (TAU), at the TA portfolio level. He/she plays a pivotal role in setting up disease area strategies, and in ensuring the quality and robustness of the medicine vision, clinical development plans and the integrated evidence plans for the TA assets in order to support the development, approval, commercialization and patient access todifferentiated medicines with proven value and with a positive return on investment for GSK. HUPs contribute to Medical Governance at the organizational level.  Responsibilities: o Work across boundaries  In partnership with development communities (EDLs, DPU Heads, and MDLs, Medical,  VEO Commercial), the Head of Clinical Development provides input on clinical plans, medical governance at a TA level and ensure appropriate and adequate clinical resourcing; In partnership with Franchise he/she defines disease area strategies and priorities, ensures patient focus and robust evidence package to support successful commercialization and patient access to GSK medicines; In partnership with GCSP, he/she is accountable for safe and ethical conduct of studies at the TA level.   o Release energy   The Head of Clinical Development leads a team of empowered and motivated clinical development staff, creates an environment where real conversations, healthy challenge and innovation is encouraged to enable effective decision-making. He/she creates a compelling vision and achieve great alignment around the work that needs to be done to deliver the TA pipeline and takes responsibility for managing issues as they arise i.e. finds and delivers solutions. o Develop capability and talent  He/she champions Clinical Excellence at the TA level through talent identification, recruitment,  management and development of a team of high performing clinical staff (physicians and clinical scientists), and implement plans to address current and future capability needs o Drive performance  He/she ensures timely and high quality delivery of Innovative clinical trials including all documents and submissions at the TAU level, lead clinical trial innovation and optimization efforts to drive consistency, efficiency and teamwork across programs level. o Live our values  He/she is the single point of accountability for medical governance at the TA level. HUPs ensure  adequate clinical oversight of clinical research initiatives, and provide a global and objective viewpoint of safety and efficacy by cultivating and sustaining a culture of openness and transparency with patient well-being as the key driver in decision-making Compliance: Global Requirements and Local Requirements  Ensure that Medical Governance for the TA is conducted in compliance with all GSK Policies, GSK SOPs, and applicable global and local regulatory guidance (GCP).  The HUP is accountable to ensure that all physicians and clinical staff are conducting activities according to GCP and are fully trained and aware of these requirements. The Head of Clinical Development is accountable to ensure that medical governance is considered for non-clinical issues and activities and to address any items which might impact clinical conduct or patient safety in study. He/she is accountable to ensure safety issues are escalated to the appropriate TA and GMG level and tocommunicate to TA medical and clinical staff items of importance related to clinical conduct or patient safety. EXPERIENCE / ACCOUTABILITIES Accountable for Clinical Components of Medicine Development of all assets in TA: o Provides a single Clinical Development/Medical point of contact for the TA and its portfolio to the leadership of the MDTs, DPUs, the preclinical function leads, as well as Medical Affairs, Commercial, Health Outcomes and other relevant functional partners in establishing disease area strategy and E2E medicine vision;  o Leads pipeline delivery by ensuring accuracy, quality and timeliness of CDPs, as well as clinical components of required regulatory and market access submissions, throughout the life cycle; o Leads project oversight to ensure timely, efficient, and compliant delivery of clinical activities according to GSK metrics and policies, working with the PCPS TAU lead. o Provides advice and guidance on specific clinical development, marketed product management, and safety/efficacy issues  Accountable for Medical Governance  o Provides clinical/medical leadership, advice, and guidance for the accountable PPLs to ensure overall safety of study subjects and scientific integrity of GSK clinical trials o Supports/Foster interactions with the Global, Regional, or Local Medical Affairs Leaders in their accountability for Medical Governance of interactions with external communities about science and medicine (including the provision of medical information to healthcare professionals) and promotional practices are conducted to the highest standard o Supports & Foster interactions with the GCSP leaders in their accountability for Pharmacovigilance to protect patient safety and wellbeing o Ensures timely and proper disclosure of clinical research and results Develop, manage, and allocate clinical resources across projects and programs  o Attract, retain and mentor clinical staff  o Manage clinical resource across discovery/early stage programs, late stage projects, marketed product programs, due diligence activities, and other clinical activities within the TAU according to the priorities of the portfolio Results:  Enhance delivery & improve end-to-end pipeline productivity and IRR o A clear disease area strategy, medicine vision and OneCDP/IEP  o excellent medical governance of all clinical trial activities o robust scientific engagement of external stakeholders o effective and dynamic clinical resource allocation especially in high priority projects Drive simplification and reduce complexity across R&D o Fully outsourced clinical studies where appropriate o Explore opportunities for simplification at TA level and organizational level LI-GSK Please provide a Cover Letter as this will be reviewed closely as part of the application review process. Why You? Basic qualifications:  o Medical Doctor with Board Qualification (or equivalent) in Medical Oncology or related Oncology Specialty.   o Significant pharmaceutical Oncology therapy area clinical development leadership experience. o Experience managing a team of comparable size across multiple levels in an oncology clinical development organization is required. o Keen understanding of oncology drug development especially late phase registration trials to include trial design and protocol development o Experience with clinical development of cell-based therapy, cancer immunotherapies and/or cancer epigenetics modifiers is a plus o Relevant experience in early phase drug development is an advantage o Proven ability to strategize, prioritize, and manage multiple projects simultaneously to ensure quality, timely, on-target and within budget accomplishment of tasks. o Ability to pay attention to detail while discriminating between critical and non-critical activities, and to follow established processes while identifying areas for process improvement o Attention to detail with excellent planning, time management and organizational skills o Excellent communication and presentation skills, high- level negotiation skills and the ability to resolve conflict in a constructive manner Preferred qualifications:  MD/PhD Required degrees: Medical Doctor Experience required: 10 years Requisition ID: WD162834
Salary Range: NA
Minimum Qualification
8 - 10 years

Don't Be Fooled

The fraudster will send a check to the victim who has accepted a job. The check can be for multiple reasons such as signing bonus, supplies, etc. The victim will be instructed to deposit the check and use the money for any of these reasons and then instructed to send the remaining funds to the fraudster. The check will bounce and the victim is left responsible.